Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

rally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions.  Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statem
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
(Date:11/26/2014)... 2014 Silicon Valley Electronic Data Capture ... RPM Alliance , provider of clinical research and data ... latest addition to its CRO Partnership Program, Clinovo expands ... to India. , “We have found Clinovo’s ClinCapture ... EDC platform which is both user friendly and easy ...
(Date:11/26/2014)... Global biostimulants market is expected to reach ... CAGR of 12.5%. In order to cater to ... ecological impacts, farmers are looking to adopt natural ... more effectively & efficiently. Biostimulants are consequently seen ... on investments. , Leading companies in the biostimulants ...
(Date:11/26/2014)... 2014 CURE™ magazine will ... December 5, 2014, in San Francisco prior to the ... event will honor clinicians, caregivers, and advocates who have ... (MPNs). , Special guest speaker Charles Esten, from ... journey at the reception. Over a decade ago, ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna ... company focused on,endocrine therapy and oncology, will announce ... live webcast presentation and conference call hosted by,President ... the outcome,of management,s review of the Company,s pipeline ...
... /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) announced today that Gregory M.,McKee, the ... conferences: BioContact Quebec 2007 (Quebec, Canada): ... Mr. McKee is scheduled to present on Thursday, October 4th at ... Salle Laval Room at the Fairmont Le ...
... Pa., Oct. 2 Monitorforhire.com, the,fastest source ... its,service even faster. The company has added ... and respond immediately to work requests via,PDA ... Scott Freedman, president of monitorforhire.com says ...
Cached Biology Technology:AEterna Zentaris Announces Outcome of Management's Strategic Review 2AEterna Zentaris Announces Outcome of Management's Strategic Review 3AEterna Zentaris Announces Outcome of Management's Strategic Review 4Nventa's CEO to present at two upcoming investor conferences 2
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Calif., May 11, 2010 -- Investigators from around the ... Friday, May 7, to share their knowledge of the ... nucleic acids turn off proteins and have been implicated ... other conditions. "The discovery that small RNAs ...
... University have developed a rapid, high-throughput screening method for ... by Munkongdee et al, "Rapid diagnosis of α-thalassemia by ... of The Journal of Molecular Diagnostics . ... defect in the production of a component of hemoglobin. ...
... the 40 th annual meeting of the Society ... research findings on the brain, nervous system, and related ... meeting is the world,s largest source of emerging news ... will discuss how science and society can work together ...
Cached Biology News:Researchers share insights into RNA 2Actress Glenn Close to address stigma of mental illness at world's largest brain science meeting 2Actress Glenn Close to address stigma of mental illness at world's largest brain science meeting 3
... Immunogen: synthetic peptide corresponding to the third ... dopamine receptor, conjugated to KLH. The immunizing ... and mouse gene. Physical form: Solution ... 0.01% sodium azide. Titertest method: IHC ...
... PCR Workstation brings together UV irradiation ... dual-attack environment against PCR contamination! Quickly ... Maintain a clean environment with antimicrobial ... and reagents within minutes with built-in 30-minute ...
... Recombinant Enterokinase (rEK) is a highly ... bovine enterokinase, a serine protease which recognizes ... enzyme (AspAspAspAspLys?) and has similar enzymatic activity ... coli and purified to yield the highest ...
... benefits of a Hybridizer and UV Crosslinker (254nm ... , This unique, new design for ... at one location , Hybridizer and Crosslinker ... other , The Crosslinker is also available ...
Biology Products: